Características farmacocinéticas diferenciales de micafungina. Experiencia en poblaciones especiales

Grau Cerrato, Santiago; Pardos, Sonia Luque; Quirante, Olivia Ferrández.
Enferm. infecc. microbiol. clín. (Ed. impr.) ; 29(supl.2): 10-14, mar. 2011. tab
Artículo en Español | IBECS (España) | ID: ibc-95792

Documentos relacionados

  1. Liposomal amphotericin B-the past.
  2. Altered Micafungin Pharmacokinetics in Intensive Care Unit Patients.
  3. Tissue penetration of antifungal agents.
  4. Pharmacokinetics of nebulized and subcutaneously implanted terbinafine in cottonmouths (Agkistrodon piscivorus).
  5. Pharmacokinetics of micafungin in patients undergoing allogeneic hematopoietic stem cell transplantation.
  6. Terbinafine in combination with other antifungal agents for treatment of resistant or refractory mycoses: investigating optimal dosing regimens using a physiologically based pharmacokinetic model.
  7. Clinical pharmacokinetics and outcomes of oral fluconazole therapy in dogs and cats with naturally occurring fungal disease.
  8. Population pharmacokinetics and pharmacodynamics of caspofungin in pediatric patients.
  9. Influence of switching from intravenous to oral administration on serum voriconazole concentration.
  10. Impact of collagen-induced arthritis on the pharmacokinetic disposition of voriconazole, a widely used antifungal agent: in vitro and in vivo investigations in DBA/1J mice.